Baricitinib in Patients with Inadequate Response or Intolerance to Conventional Synthetic DMARDs: Results from the RA-BUILD Study
Ann Rheum Dis 2017;76:88–95.
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Ann Rheum Dis 2017;76:88–95.
Arthritis Res Ther 2016; 18:198. DOI.10.1186/s13075-016-9
Rheumatology (Oxford) 2016; DOI 10.1093/rheumatology/kew325
Arthritis Rheumatol 2016; Accepted article DOI 10.1002/art-39808 [Epub 2016]
Ann Rheum Dis 2016;0:1–7 DOI 10.1136/annrheumdis-2016-209773.
Drug Saf. 2016 June 9; 39:755–762; DOI 10.1007/s40264-016-0431-z [Epub ahead of print]
Clin Ther. 2016 Mar 28. doi: 10.1116/j.clinthera. 2016.03.038 [Epub ahead of print]
Strand et al. Rheumatology (Oxford). 2016 Feb 29. doi:pii: kev442. [Epub ahead of print]
Autoimmunity Reviews Doi: 10.1016/j.autrev.2016.01.010
Arthritis Research & Therapy (2015) 17:319 DOI: 10.1186/s13075-015-0835-7